Ravindra Majeti
Gründer bei Orbital Therapeutics, Inc.
Profil
Ravindra Majeti is the founder of Forty Seven, Inc. which was founded in 2014.
He held the title of Independent Director at Forty Seven, Inc. from 2015 to 2020.
Dr. Majeti is also the founder of Pheast Therapeutics Inc, Orbital Therapeutics, Inc...
Dr. Majeti's current job is as an Associate Professor at Stanford University since 2009.
He is also a Member at the Institute For Stem Cell Biology & Regenerative Medicine.
Dr. Majeti's former job was as a Director at BeyondSpring, Inc. from 2020 to 2021.
Dr. Majeti's education includes an undergraduate degree from Harvard University and a doctorate degree from The University of California, San Francisco.
Aktive Positionen von Ravindra Majeti
| Unternehmen | Position | Beginn |
|---|---|---|
| Stanford University | Corporate Officer/Principal | 01.01.2009 |
| Institute For Stem Cell Biology & Regenerative Medicine | Corporate Officer/Principal | - |
Orbital Therapeutics, Inc.
 Orbital Therapeutics, Inc. BiotechnologyHealth Technology Orbital Therapeutics, Inc. is a company based in Cambridge, MA that aims to enhance health by utilizing RNA-based medicines to treat human diseases in innovative ways. The company is building a platform that combines RNA technology delivery methods, data science, and automation to develop a portfolio of medicines focused on vaccines, immunomodulation, protein replacement, and regenerative medicine. The company was founded by Drew Weissman, John M. Maraganore, Kristina M. Burow, Ravindra Majeti, Giuseppe Ciaramella, Eugene W. Yeo, Howard Y. Chang, and Carol Suh, with Giuseppe Ciaramella serving as the CEO since incorporation. | Gründer | - |
Ehemalige bekannte Positionen von Ravindra Majeti
| Unternehmen | Position | Ende |
|---|---|---|
| BEYONDSPRING INC. | Direktor/Vorstandsmitglied | 22.12.2021 |
| FORTY SEVEN, INC. | Gründer | 07.04.2020 |
Pheast Therapeutics Inc
 Pheast Therapeutics Inc BiotechnologyHealth Technology Pheast Therapeutics Inc is a pre-clinical stage immuno-oncology company that focuses on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. The company is based in Palo Alto, CA. Pheast aims to develop novel therapies for some of the most difficult-to-treat and aggressive cancers, as well as women's cancers including ovarian cancer and breast cancer. The company was founded in 2020 and is led by scientific experts in innate immunity and cancer immunotherapy. Jacopo Leonardi has been the CEO of the company since 2023. | Gründer | - |
Ausbildung von Ravindra Majeti
| Harvard University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BEYONDSPRING INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
| Institute For Stem Cell Biology & Regenerative Medicine | |
Pheast Therapeutics Inc
Pheast Therapeutics Inc BiotechnologyHealth Technology Pheast Therapeutics Inc is a pre-clinical stage immuno-oncology company that focuses on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. The company is based in Palo Alto, CA. Pheast aims to develop novel therapies for some of the most difficult-to-treat and aggressive cancers, as well as women's cancers including ovarian cancer and breast cancer. The company was founded in 2020 and is led by scientific experts in innate immunity and cancer immunotherapy. Jacopo Leonardi has been the CEO of the company since 2023. | Health Technology |
Orbital Therapeutics, Inc.
Orbital Therapeutics, Inc. BiotechnologyHealth Technology Orbital Therapeutics, Inc. is a company based in Cambridge, MA that aims to enhance health by utilizing RNA-based medicines to treat human diseases in innovative ways. The company is building a platform that combines RNA technology delivery methods, data science, and automation to develop a portfolio of medicines focused on vaccines, immunomodulation, protein replacement, and regenerative medicine. The company was founded by Drew Weissman, John M. Maraganore, Kristina M. Burow, Ravindra Majeti, Giuseppe Ciaramella, Eugene W. Yeo, Howard Y. Chang, and Carol Suh, with Giuseppe Ciaramella serving as the CEO since incorporation. | Health Technology |
